SCHEMBL3948181

SCHEMBL3948181

O=S(=O)(Cl)c1cc(Cl)c(F)cc1Cl

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPV4 Q9HBA0 2/20 0.46
CA1 P00915 3/20 0.34
CA2 P00918 3/20 0.34
KDM1A O60341 2/20 0.34
CA9 Q16790 2/20 0.34
KDM1B Q8NB78 1/20 0.34
PTGES2 Q9H7Z7 2/20 0.34
ALDH1A1 P00352 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
CA12 O43570 1/20 0.33
CA3 P07451 1/20 0.33
CA4 P22748 1/20 0.33
CA6 P23280 1/20 0.33
CA5A P35218 1/20 0.33
CA7 P43166 1/20 0.33
CA14 Q9ULX7 1/20 0.33
CA5B Q9Y2D0 1/20 0.33
SOS1 Q07889 2/20 0.33
L3MBTL1 Q9Y468 1/20 0.32
PTGS2 P35354 4/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3912870 0.91 TRPV4 (0.46) TRPV4CA1CA2CA9PTGES2
SCHEMBL1036725 0.88 TRPV4 (0.47) TRPV4CA1CA2CA9PTGES2
SCHEMBL30485974 0.86 TRPV4 (0.41) TRPV4CA1CA2KDM1ACA9
SCHEMBL1501202 0.86 TRPV4 (0.41) TRPV4CA1CA2KDM1ACA9
SCHEMBL320432 0.86 TRPV4 (0.41) TRPV4CA1CA2CA9PTGES2
SCHEMBL29669013 0.86 TRPV4 (0.41) TRPV4CA1CA2CA9PTGES2
SCHEMBL29669007 0.86 TRPV4 (0.41) TRPV4CA1CA2CA9PTGES2
SCHEMBL1991714 0.85 TRPV4 (0.50) TRPV4CA1CA2CA9ALDH1A1
SCHEMBL26978287 0.84 TRPV4 (0.44) TRPV4CA1CA2CA9CA12
SCHEMBL29503458 0.84 TRPV4 (0.42) TRPV4CA1CA2CA9PTGES2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090264431-A1 NOVEL CATHEPSIN C INHIBITORS AND THEIR USE GLAXO GROUP LIMITED (GB) 2009-10-22 US disclosed
US-20090264431-A1 NOVEL CATHEPSIN C INHIBITORS AND THEIR USE GLAXO GROUP LIMITED (GB) 2009-10-22 US disclosed
US-20090264431-A1 NOVEL CATHEPSIN C INHIBITORS AND THEIR USE GLAXO GROUP LIMITED (GB) 2009-10-22 US disclosed
WO-2009026197-A1 NOVEL CATHEPSIN C INHIBITORS AND THEIR USE GLAXO GROUP LIMITED (GB) 2009-02-26 WO disclosed
WO-2009026197-A1 NOVEL CATHEPSIN C INHIBITORS AND THEIR USE GLAXO GROUP LIMITED (GB) 2009-02-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264431-A1 NOVEL CATHEPSIN C INHIBITORS AND THEIR USE CTSB, CTSS, CTSF TRPV4 4201/4885CA1 1144/4885CA2 212/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.